Found 3298 clinical trials
A Randomized, double-blind, parallel-group, 12-week, chronic-dosing, multi-center study to assess the efficacy and safety of PT010 compared to PT009 in subjects with moderate to very severe chronic obstructive pulmonary disease (COPD).
obstructive pulmonary disease (COPD).
- 548 views
- 25 Mar, 2021
- 1 location
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
This is a Phase 3, Randomized, Double-Blind, Placebo-Controlled study to assess the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations and pulmonary function in former smokers with moderate to severe COPD.
- 0 views
- 07 Jul, 2023
- 1 location
A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment
patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment
- 1324 views
- 23 Nov, 2020
- 1 location
Pacific 4: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.
- 0 views
- 26 Aug, 2022
- 1 location
A Phase III, 52-week, Multinational, Multicenter, Randomized, Double-blind, 2-arm Parallel Group Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide (CHF 5993) With the Fixed Dose Dual Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate (CHF 1535), Both Administered Via pMDI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the
- 0 views
- 07 Jul, 2023
- 1 location
Low-Dose Danazol for the Treatment of Telomere Related Diseases
can develop diseases of the bone marrow, lung, and liver. Researchers want to see if low doses of the hormone drug danazol can help.
- 348 views
- 22 Dec, 2020
- 1 location
Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that becomes worse over time. There is currently no effective treatment for it. Researchers
- 178 views
- 23 Nov, 2020
- 1 location
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with advanced malignancies. This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with …
- 262 views
- 10 May, 2022
- 4 locations
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With MTAP Homozygous Deletion
This is a Phase 1/2, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
- 0 views
- 02 Aug, 2022
- 6 locations
Longitudinal Observational Study of Severe Asthma
Background: Asthma is a lung condition that causes difficulty breathing and decreased lung function. Some people with asthma have more severe disease symptoms. They
- 30 views
- 22 Dec, 2020
- 1 location